Kala is backed by leading life science investors.
AbbVie’s investment in Kala is managed through AbbVie’s Ventures & Early Stage Collaborations (VESC) Group dedicated to making venture capital investments in emerging biotech companies, licensing/acquiring pre-Phase 1 compounds and expanding academic partnerships. Unlike traditional venture capital firms, AbbVie characterizes an investment’s success by its potential to significantly increase AbbVie’s strategic growth, and not solely by its financial return.
* – AbbVie is a stockholder of Kala and has the right to appoint one director to the nine member Kala Board. AbbVie is not otherwise affiliated with Kala and AbbVie does not control, is not controlled by and is not under common control with Kala and is not an affiliate as defined under any applicable statute, rule, regulation or law.
Lux Capital Management
Lux Capital is a leading venture firm focused on founding, seed, and early stage investments in emerging technologies. Lux takes an active role in helping entrepreneurs build successful businesses in Energy, Life Sciences, and Technology. The Lux investment team has founded more than 20 companies from scratch, including Caliper, Genocea, Illumina, Kala, Kurion, Lux Research, Nanosys, Neurocrine Biosciences, and Vertex Pharmaceuticals. For more information please visit www.luxcapital.com.
Polaris Partners invests in exceptional technology and healthcare companies across all stages of their lifecycles. With offices in Boston, San Francisco, and Dublin, we partner globally with an unparalleled network of repeat entrepreneurs, top scientists and emerging innovators who are making significant contributions in their fields and vastly improving the way in which we live and work. For more information please visit www.polarispartners.com.
Third Rock Ventures
Third Rock Ventures is a leading healthcare venture firm focused on investing and launching companies that make a difference in people’s lives. The Third Rock team has a unique vision for ideating and building transformative healthcare companies. Working closely with our strategic partners and entrepreneurs, Third Rock has an extensive track record for managing the value creation path to deliver exceptional performance. For more information please visit www.thirdrockventures.com.
Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. We target the entire healthcare and biotechnology industry, with a special focus on pharmaceuticals, diagnostics and medical devices. Founded in 2008, Ysios Capital has €118 million in assets under management distributed over two funds. The second fund has a target size of €100 million and will remain open to new investors until September 2015. For more information please visit www.ysioscapital.com.